(Q37712177)

English

The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?

scientific article published on January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 August 2017

The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities? (English)

1 reference

Europe PubMed Central

22 August 2017

vector-borne disease

0 references

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

author name string

Mayilsamy Muniaraj

1

1 reference

Europe PubMed Central

22 August 2017

publication date

1 January 2014

1 reference

Europe PubMed Central

22 August 2017

Tropical Parasitology

1 reference

Europe PubMed Central

22 August 2017

4

1 reference

Europe PubMed Central

22 August 2017

1

1 reference

Europe PubMed Central

22 August 2017

10-19

1 reference

Europe PubMed Central

22 August 2017

Leishmania donovani develops resistance to drug combinations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Insecticide susceptibility of Phlebotomus argentipes in visceral leishmaniasis endemic districts in India and Nepal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Treatment of visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Combination therapy for visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Can visceral leishmaniasis be eliminated from Asia?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

The relationship between leishmaniasis and AIDS: the second 10 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Injectable paromomycin for Visceral leishmaniasis in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Vector control in leishmaniasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Drug unresponsiveness & combination therapy for kala-azar

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Visceral leishmaniasis (kala-azar): challenges ahead

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Laboratory diagnosis of visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Epidemiology of visceral leishmaniasis in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Comparison of regimens of treatment with sodium stibogluconate in kala-azar

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 August 2017

Transmission dynamics and underreporting of Kala-azar in the Indian state of Bihar

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

6 September 2017

Leishmaniasis and poverty

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

6 September 2017

Drug resistance in Indian visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

6 September 2017

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

6 September 2017

Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

14 September 2017

Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

14 September 2017

Amphotericin B in resistant kala-azar in Bihar

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

28 September 2017

Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 June 2018

Vector density and the control of kala-azar in Bihar, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 June 2018

Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

23 June 2018

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

1 September 2018

A report on the indoor residual spraying (IRS) in the control of Phlebotomus argentipes, the vector of visceral leishmaniasis in Bihar (India): an initiative towards total elimination targeting 2015 (Series-1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

1 September 2018

Newer strategies for the kala-azar elimination programme in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

1 September 2018

A new strategy for elimination of kala-azar from rural Bihar.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

1 September 2018

Resistance of sandflies to DDT in Kala-azar endemic districts of Bihar, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

1 September 2018

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

1 September 2018

Control of the leishmaniases. Report of a WHO Expert Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992795

2 October 2018

Visceral Leishmaniasis and HIV Coinfection in Bihar, India

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The leishmaniases. Report of a WHO Expert Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Occurrence & significance of kala-azar in Bhutan

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kala-Azar (visceral leishmaniasis) and HIV coinfection in Bihar, India: is this combination increasing?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of kala-azar--new approaches to an old problem

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical profile of cases of kala-azar in Bihar

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new focus of visceral leishmaniasis in sub-Himalayan (Kumaon) region of northern India

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success

1 reference

https://pubmed.ncbi.nlm.nih.gov/24754021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4103/2229-5070.129143

1 reference

Europe PubMed Central

22 August 2017

release_5jsvmm5zvjc4vdqz36n6ex3mre

1 reference

https://api.fatcat.wiki/v0/release/5jsvmm5zvjc4vdqz36n6ex3mre

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37712177&oldid=1842906363"